These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Crizotinib (xalkori) for non-small cell lung cancer. Med Lett Drugs Ther; 2012 Feb; 54(1383):11-2. PubMed ID: 22354221 [No Abstract] [Full Text] [Related]
4. Src inhibitors in lung cancer: current status and future directions. Rothschild SI; Gautschi O; Haura EB; Johnson FM Clin Lung Cancer; 2010 Jul; 11(4):238-42. PubMed ID: 20630825 [TBL] [Abstract][Full Text] [Related]
5. Two drugs beat back lung tumors. Cancer Discov; 2015 Feb; 5(2):100. PubMed ID: 25656878 [No Abstract] [Full Text] [Related]
6. Using EGFR status to personalize treatment: lung cancer researchers reach a milestone. Friedrich MJ J Natl Cancer Inst; 2009 Aug; 101(15):1039-41. PubMed ID: 19638503 [No Abstract] [Full Text] [Related]
7. A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium. Laurie SA; Goss GD; Shepherd FA; Reaume MN; Nicholas G; Philip L; Wang L; Schwock J; Hirsh V; Oza A; Tsao MS; Wright JJ; Leighl NB Clin Lung Cancer; 2014 Jan; 15(1):52-7. PubMed ID: 24169259 [TBL] [Abstract][Full Text] [Related]
8. Emerging therapeutic targets in non-small cell lung cancer. Dy GK; Adjei AA Proc Am Thorac Soc; 2009 Apr; 6(2):218-23. PubMed ID: 19349491 [TBL] [Abstract][Full Text] [Related]
9. Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization--why, when, and how? Dziadziuszko R; Hirsch FR; Varella-Garcia M; Bunn PA Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4409s-4415s. PubMed ID: 16857819 [TBL] [Abstract][Full Text] [Related]
11. Multitargeted receptor tyrosine kinase inhibition: an antiangiogenic strategy in non-small cell lung cancer. Socinski MA Cancer Treat Rev; 2011 Dec; 37(8):611-7. PubMed ID: 21641723 [TBL] [Abstract][Full Text] [Related]
12. SRC promotes survival and invasion of lung cancers with epidermal growth factor receptor abnormalities and is a potential candidate for molecular-targeted therapy. Leung EL; Tam IY; Tin VP; Chua DT; Sihoe AD; Cheng LC; Ho JC; Chung LP; Wong MP Mol Cancer Res; 2009 Jun; 7(6):923-32. PubMed ID: 19491201 [TBL] [Abstract][Full Text] [Related]
13. Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go. Patel JD; Pasche B; Argiris A Crit Rev Oncol Hematol; 2004 Jun; 50(3):175-86. PubMed ID: 15182824 [TBL] [Abstract][Full Text] [Related]
14. [II. Development and Future Prospects of the Third-Generation EGFR-Tyrosine Kinase Inhibitor]. Sakata S; Iwama E; Okamoto I Gan To Kagaku Ryoho; 2015 Aug; 42(8):935-9. PubMed ID: 26353390 [No Abstract] [Full Text] [Related]
16. More than just an oncogene translocation and a kinase inhibitor: Kevin's story. Costa DB J Clin Oncol; 2012 Jan; 30(1):110-2. PubMed ID: 22067391 [No Abstract] [Full Text] [Related]
17. [Discovery and development of alectinib hydrochloride (ALECENSAR capsule 20 mg and 40 mg) ]. Yoshimura Y; Sakamoto H; Tanaka T; Inagaki N; Uzu M Nihon Yakurigaku Zasshi; 2015 Jun; 145(6):318-24. PubMed ID: 26063155 [No Abstract] [Full Text] [Related]
18. Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors. Amler LC; Goddard AD; Hillan KJ Cold Spring Harb Symp Quant Biol; 2005; 70():483-8. PubMed ID: 16869787 [TBL] [Abstract][Full Text] [Related]